Versatile antibody technology allows design of long-acting antibodies with tailored target-dependent mode of actions

by University of OsloREW enhances phagocytosis of gram-positive and killing of gram-negative bacteria. Credit:Nature Communications(2024). DOI: 10.1038/s41467-024-46321-9Antibody ther

Updated on: March 19,2024

Versatile antibody technology allows design of long-acting antibodies with tailored target-dependent mode of actions

by University of OsloREW enhances phagocytosis of gram-positive and killing of gram-negative bacteria. Credit:Nature Communications(2024). DOI: 10.1038/s41467-024-46321-9Antibody ther

Updated on:March 19,2024

HDL composition may help predict health risks and design therapeutics

by Pat Bailey,UC DavisNutrition researcher Angela Zivkovic and colleagues have found that the amounts and specific structure of complex sugars called glycans can powerfully influence the body’s

Updated on: April 16,2024

HDL composition may help predict health risks and design therapeutics

by Pat Bailey,UC DavisNutrition researcher Angela Zivkovic and colleagues have found that the amounts and specific structure of complex sugars called glycans can powerfully influence the body’s

Updated on:April 16,2024

Depemokimab cuts exacerbation rate in eosinophilic asthma

by Elana GotkineFor patients with severe asthma with an eosinophilic phenotype, depemokimab reduces the annualized rate of exacerbations, according to a studypublishedonline Sept. 9 in the

Updated on: October 01,2024

Depemokimab cuts exacerbation rate in eosinophilic asthma

by Elana GotkineFor patients with severe asthma with an eosinophilic phenotype, depemokimab reduces the annualized rate of exacerbations, according to a studypublishedonline Sept. 9 in the

Updated on:October 01,2024

Increased use of partial knee replacement could save the NHS £30 million per year

by University of OxfordCredit: NDORMSNew research from a randomised clinical trial published today inThe Lancetand funded by the National Institute for Health Research (NIHR) shows th

Updated on: March 28,2024

Increased use of partial knee replacement could save the NHS £30 million per year

by University of OxfordCredit: NDORMSNew research from a randomised clinical trial published today inThe Lancetand funded by the National Institute for Health Research (NIHR) shows th

Updated on:March 28,2024

Risankizumab safe, effective at 52 weeks for psoriatic arthritis

by Lori SolomonRisankizumab provides long-term benefits in patients with psoriatic arthritis (PsA) who have not achieved adequate response to previous therapies, according to a study recently publishe

Updated on: June 01,2024

Risankizumab safe, effective at 52 weeks for psoriatic arthritis

by Lori SolomonRisankizumab provides long-term benefits in patients with psoriatic arthritis (PsA) who have not achieved adequate response to previous therapies, according to a study recently publishe

Updated on:June 01,2024

Program may help patients with rheumatic diseases quit smoking

by WileyCredit: CC0 Public DomainSmoking increases symptoms and health risks for patients with rheumatic diseases, but interventions to help patients quit are rarely available at rheumatology cli

Updated on: March 28,2024

Program may help patients with rheumatic diseases quit smoking

by WileyCredit: CC0 Public DomainSmoking increases symptoms and health risks for patients with rheumatic diseases, but interventions to help patients quit are rarely available at rheumatology cli

Updated on:March 28,2024

Omega 3 fatty acids may reduce bacterial lung infections associated with COPD

by Suzanne Pallo,University of Rochester Medical CenterCompounds derived from omega-3 fatty acids – like those found in salmon – might be the key to helping the body combat lung infections, acco

Updated on: April 20,2024

Omega 3 fatty acids may reduce bacterial lung infections associated with COPD

by Suzanne Pallo,University of Rochester Medical CenterCompounds derived from omega-3 fatty acids – like those found in salmon – might be the key to helping the body combat lung infections, acco

Updated on:April 20,2024

Takayasu arteritis, ulcerative colitis co-occurrence rate high

(HealthDay)—Takayasu arteritis (TAK) has a high rate of co-occurrence and genetic overlap with ulcerative colitis (UC), according to a study published in the August issue ofArthritis & Rheum

Updated on: March 24,2024

Takayasu arteritis, ulcerative colitis co-occurrence rate high

(HealthDay)—Takayasu arteritis (TAK) has a high rate of co-occurrence and genetic overlap with ulcerative colitis (UC), according to a study published in the August issue ofArthritis & Rheum

Updated on:March 24,2024

FDA approves first interchangeable biosimilar for inflammatory diseases

(HealthDay)—The first interchangeable biosimilar product to Humira (adalimumab) was approved by the U.S. Food and Drug Administration on Oct. 15, the agency announced Monday.Cyltezo (adalimumab-adbm),

Updated on: June 17,2024

FDA approves first interchangeable biosimilar for inflammatory diseases

(HealthDay)—The first interchangeable biosimilar product to Humira (adalimumab) was approved by the U.S. Food and Drug Administration on Oct. 15, the agency announced Monday.Cyltezo (adalimumab-adbm),

Updated on:June 17,2024

Researchers discover key metabolic process responsible for rapid immune responses

by Children's Hospital of PhiladelphiaCredit: Pixabay/CC0 Public DomainResearchers from Children's Hospital of Philadelphia (CHOP) identified a key metabolite in cells that helps direct i

Updated on: March 19,2024

Researchers discover key metabolic process responsible for rapid immune responses

by Children's Hospital of PhiladelphiaCredit: Pixabay/CC0 Public DomainResearchers from Children's Hospital of Philadelphia (CHOP) identified a key metabolite in cells that helps direct i

Updated on:March 19,2024

Continuation vs. discontinuation of bDMARDs during the perioperative period

by Wolters Kluwer HealthCredit: Pixabay/CC0 Public DomainFor patients with rheumatic arthritis and other chronic inflammatory diseases, discontinuing biologic disease-modifying anti-rheumatic dru

Updated on: June 26,2024

Continuation vs. discontinuation of bDMARDs during the perioperative period

by Wolters Kluwer HealthCredit: Pixabay/CC0 Public DomainFor patients with rheumatic arthritis and other chronic inflammatory diseases, discontinuing biologic disease-modifying anti-rheumatic dru

Updated on:June 26,2024

Long-term rituximab safe for patients with wegener's

Repeated and prolonged use of rituximab for B-cell depletion to treat relapses or maintain remission is safe and effective in patients with refractory granulomatosis with polyangiitis (GPA; Wegener&#3

Updated on: March 28,2024

Long-term rituximab safe for patients with wegener's

Repeated and prolonged use of rituximab for B-cell depletion to treat relapses or maintain remission is safe and effective in patients with refractory granulomatosis with polyangiitis (GPA; Wegener&#3

Updated on:March 28,2024